» CombiGene comments on positive news for Bluebird
» PolarCool's strategy for international expansion
» Iconovo raises the bar in its financial goals
» Aptahem's new CMO on his role and visions
» Last clinic visit completed in Promore Pharma's enserepeptide study
Read BioStock's newsletter for v.24 here.
Morning news
Ultimovacs Cancer vaccine UV1 shows strong survival in phase I study with malignant melanoma. Read more.
Medfield Diagnostics announces that MD100 Strokefinder meets the requirements set out in the new requirements of the Medical Device Regulation. Read more.
Today is the last day to trade with Carbiotix BTU and first day of trading in warrants of series TO 1. Read more.
Abliva arranges Fireside Chat in Lund and Stockholm. Read more.
Invent Medic signs a framework agreement with Region Jönköping for Efemia continence support. Read more.
Interview with Lumitos CEO published. Read more.
BioPorto appoints Prasad Devarajan to senior medical director. Read more.
Egetis appoints Sara Melton to the company's CEO for operations in North America. Read more.
See the presentations from BioStock Life Science Spring Summit!
Notifications of share transactions and changes in equity:
News received since Friday lunch
Dicot SEK 10 million is added through the exercise of warrants of series TO 3. Read more.
Vicore decides on a set-off issue of 87 shares as part of milestone compensation. Read more.
Corline Biomedical announces that European Patent Office intends to approve further Renaparin-patent. Read more.
TLV decides to include Bristol Myers Squibbs Zeposia in the drug benefit for the treatment of adults with moderately to severely active ulcerative colitis. Read more.
The decision of WTO Partially repealing intellectual property rights on vaccines against Covid-19 is deeply unfortunate, writes Lif. Read more.
The strategic innovation program Medtech4Health receives continued funding from Vinnova. Read more. Medtech4Health and Sahlgrenska Science Park invites you to an event about innovative solutions in diagnostics and treatment. Read more.
Isofol adjusts the start time for the live R&D event on June 20th to 14.00:XNUMX p.m. Read more.
This morning's price development
Winner: QLife Holding 22,5%, Medfield 20%, Lipigon Pharmaceuticals 17,3%, Eurocine Vaccines 7,9%, Implantica DDB 7,8%
Förlorare: Respiratorius -10,4%, iZafe Group B -10,3%, Annexin Pharmaceuticals -7,2%, Sprint Bioscience -6,4%, SyntheticMR -5,8%
Index: OMXS30 1896 +0,64%, Healthcare +1,15%
More articles from BioStock
» Issuance secures Hemcheck's continued expansion
» Continued growth predicted in Medicon Valley
» BrainCool reports successful outcome in stroke study
» Great interest in Toleranzia's MG concept
» Spago Nanomedical towards a clinic with a clear plan